Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Efient

- PMLiVE

NICE demands more data for Sanofi’s oral MS drug

UK body won't recommend Aubagio for NHS use based on current information

National Institute for Health and Care Excellence NICE logo

NICE questions cost of medicines development

Says pharma should determine if R&D spending of £1bn+ per drug is really necessary

- PMLiVE

The evolution of IQWiG in Germany’s drug pricing policy

Over the past ten years Germany has created a well-oiled machine designed to ensure that it gets the best deal when it comes to drug prices

Daiichi Sankyo logo

Daiichi Sankyo on track for edoxaban filing in 2014

Positive phase III data for anticoagulant

Novartis building

NICE backs Novartis’ Jetrea in rare eye condition

Recommends drug be available for NHS use to treat vitreomacular traction

- PMLiVE

Marschall Runge joins Lilly’s board of directors

Will serve on the pharma company's Science and Technology, and Public Policy and Compliance Committees

National Institute for Health and Care Excellence NICE logo

NICE turns down Afinitor for breast cancer

NHS patients in England and Wales will not have routine access to Novartis’ drug

- PMLiVE

UK market access: The importance of a local value story

Meeting the needs of the health service’s new stakeholders

Eli Lilly HQ

Lilly is latest drugmaker drawn into China crisis

Local media reports link the pharma company to doctor bribery

National Institute for Health and Care Excellence NICE logo

NICE forced to look again at Alimta

Procedural error forces watchdog to reconsider rejection of Lilly's lung cancer

- PMLiVE

Outcomes shape the new European payer networks

In the new commercial reality of cost-constrained healthcare environments the payer is everywhere

- PMLiVE

Pfizer faces NICE rejection for lung cancer drug

Xalkori not cost-effective use of NHS resources in England and Wales

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links